Polyplus, a key player in advanced biologics and cell and gene therapy production within the Sartorius Group, has entered into a collaborative venture with MarkHerz, a Korean cell and gene therapy (CGT) contract development and manufacturing organization (CDMO). This partnership aims to establish new efficiency benchmarks in CGT, with a primary focus on reducing costs and enhancing the quality of therapeutic products per dose.
The teams will join forces to optimize process efficiency, utilizing Polyplus products and expertise alongside MarkHerz's manufacturing capabilities. The project will kick off with the application of proprietary e-Zyvec® technology to design customized plasmids for high-purity manufacturing. Plasmid engineering and production services will mark the initial phase, followed by upstream optimization efforts.
Throughout this collaborative initiative, the teams will not only work on enhancing process efficiency but will also contribute to the development and exchange of local knowledge. This collaborative exchange aims to foster a broader sharing of information and expertise, ultimately advancing the field of CGT manufacturing.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!